Carlyle Group Inc vs Zoetis Inc — how do they compare? Carlyle Group Inc trades at $48.27 (market cap $17.23B), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Carlyle Group Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| CG | ZTS | |
|---|---|---|
Market Cap | $17.23B | $31.14B |
Sector | Financials | Health |
52-Week High | $69.35 | $156.76 |
52-Week Low | $40.52 | $71.91 |
Dividend Yield | 2.9% | 2.81% |
Enterprise Value | — | $38.70B |
Signals from Pluang's Aura AI — not financial advice
CG trades at $48.14, up 0.71% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates, with revenue growth and AUM expansion noted. The stock shows positive momentum near key resistance at $50, supported by institutional buying and strategic partnerships.
Outlook is positive given earnings beats and a $59.14 consensus price target, but risks include volatile cash flows and high P/E of 50.36. Investment appeal hinges on sustained fundraising and execution amid economic uncertainty.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →